The United States Department of Justice on Monday announced the terms of a settlement with GlaxoSmithKline, saying the pharmaceutical giant had agreed to plead guilty and pay $3 billion in fines to resolve criminal and civil liability from “unlawful promotion of certain prescription drugs, its failure to report certain safety data, and its civil liability for alleged false price reporting practices.”
Read the DoJ’s announcement of the settlement here.